Aptose Biosciences, Inc.
APTO
APTO was delisted on the 1st of April, 2025.
49 hedge funds and large institutions have $14.7M invested in Aptose Biosciences, Inc. in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 10 reducing their positions, and 4 closing their positions.
280% more call options, than puts
Call options by funds: $38K | Put options by funds: $10K
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
10% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 10
2% more funds holding
Funds holding: 48 → 49 (+1)
22% less capital invested
Capital invested by funds: $18.8M → $14.7M (-$4.07M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Annandale Capital
Dallas,
Texas
|
+$244K |
| 2 |
CC
Carlson Capital
Dallas,
Texas
|
+$78.6K |
| 3 |
Renaissance Technologies
New York
|
+$45.8K |
| 4 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$44.1K |
| 5 |
VF
Virtu Financial
New York
|
+$25.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SMH
Sanders Morris Harris
Houston,
Texas
|
-$281K |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$264K |
| 3 |
Morgan Stanley
New York
|
-$127K |
| 4 |
VC
Voss Capital
Houston,
Texas
|
-$76.9K |
| 5 |
D.E. Shaw & Co
New York
|
-$58K |
APTO Hedge Fund Activity: Q3 2022 in Review
49 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences, Inc. (APTO) for Q3 2022, worth a combined $14.7M — down 22% from $18.8M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new APTO positions and 4 closed out — a net gain of 1 holder — while 11 added to existing stakes and 10 trimmed.
The largest buyer was Annandale Capital, adding an estimated $244K. The largest seller was Sanders Morris Harris, cutting an estimated $281K.
- 49 institutional investors held Aptose Biosciences, Inc. (APTO) as of Q3 2022, up from 48 in Q2 2022.
- Funds reported $14.7M of Aptose Biosciences, Inc. stock for Q3 2022, down 22% quarter-over-quarter.
- 5 funds opened new Aptose Biosciences, Inc. positions in Q3 2022 and 4 closed out, a net change of +1 holder.
- The largest Aptose Biosciences, Inc. buyer in Q3 2022 was Annandale Capital, an estimated $244K added.
- The largest Aptose Biosciences, Inc. seller in Q3 2022 was Sanders Morris Harris, an estimated $281K sold.
Based on aggregated 13F filings for Q3 2022.